BG changes
Pick any two versions below to diff them.
- Price
- $90.87
- Discount category
- Close to intrinsic value
- Intrinsic value source
- AI estimate
- Next earnings
- Jan 29, 2027
- Next earnings is estimate
- Yes
- Company name
- added: Bunge Global
- Sector
- added: Agribusiness and food ingredients
- About
- added: Bunge Global SA (BG) buys, processes and sells agricultural commodities. It crushes soybeans and softseeds such as canola and sunflower into meal and oil, refines vegetable oils, makes specialty fats and ingredients, mills wheat and corn, and trades grain around the world. Its segments are Soybean Processing and Refining, Softseed Processing and Refining, Tropical Oils and Specialty Ingredients, and Grain Merchandising and Milling. Bunge combined with Viterra in July 2025, which added a large grain origination and handling network. Net sales were $69,706 million in the first nine months of 2026. Bunge is incorporated in Switzerland, has its headquarters in Chesterfield, Missouri, and its shares trade on the New York Stock Exchange.
- Thesis
- added: The market prices Bunge close to the AI estimate, because it expects the strong processing margins of 2026 to fall back. Biofuel mandates in North America, the conflict with Iran and the war in Ukraine raised demand and prices for vegetable oils in 2026, and Bunge raised its 2026 outlook for adjusted EPS from $7.50 to $8.00 to $9.25 to $9.75. Investors do not know how much of this profit is normal. The AI estimate uses a normalized EPS below the 2026 outlook. For the value to rise, three things must be true. Bunge must show savings from the Viterra combination in its results. The new oilseed processing line of Bunge Chevron Ag Renewables in Destrehan, Louisiana, which started production after Q3 2026, must add profit. The 2027 outlook must show that earnings stay above the 2025 level when margins are average. The full-year 2026 results, expected in early 2027 with the first 2027 outlook, are the next test. A rise in normalized EPS would take several years of results to prove.
- Valuation
- added: The intrinsic value for Bunge Global is an AI estimate from November 14, 2026. It is not an analyst's value. An AI research agent calculated it from the filings of Bunge with the SEC. The method is a multiple of normalized adjusted earnings per share. Normalized earnings are the earnings of an average year for processing and merchandising margins, not of a strong or a weak year. Adjusted earnings are after interest, so the estimate makes no debt adjustment. The Q3 2026 release of October 29, 2026 keeps the 2026 outlook for adjusted EPS at $9.25 to $9.75. The first 2026 outlook in the Q4 2025 release of February 4, 2026 was $7.50 to $8.00, and Bunge raised it in April and July 2026. The Q4 2025 release gives adjusted EPS of $7.57 for 2025 and $9.19 for 2024. Adjusted EPS was $6.38 in the first nine months of 2026. The Q3 2026 10-Q gives 192,143,784 registered shares outstanding at October 27, 2026 and 194,049,036 diluted weighted shares for Q3 2026. It gives total debt of $16,746 million and cash of $524 million at September 30, 2026, against readily marketable inventories of $14,696 million that Bunge can sell for cash quickly. Bunge expects net interest expense of $640 to $670 million in 2026. The normalized EPS and the multiples are assumptions. The low case assumes $7.50, the low end of the first 2026 outlook, at 10 times. It gives $75.00 per share. The base case assumes $9.00, a little below the 2026 outlook, because biofuel demand and trade disruption made 2026 margins strong, at 11.5 times. It gives $103.50 per share. The high case assumes $11.00, with savings from the Viterra combination and the new Destrehan processing line, at 12.5 times. It gives $137.50 per share. The estimate assumes weights of 25%, 50% and 25%. The weighted intrinsic value is $104.88 per share. Processing margins change with crops, trade policy and biofuel rules, so normalized EPS is hard to predict. Efficient scale and cost advantage are the possible sources of a lasting edge. Bunge has a large global network of processing plants, ports and grain elevators, and the Viterra combination of July 2025 made it larger. But its margins depend on markets that Bunge does not control, and other large merchants have similar networks. Switching costs and network effects are weak, because customers buy commodities on price. As of Nov 14, 2026.
- Risks
- added: Processing margins depend on crops, trade flows, biofuel rules and the wars in Ukraine and the Middle East. A change in US biofuel policy or the end of trade disruption can reduce margins fast. Total debt was $16,746 million at September 30, 2026, up from $14,051 million at December 31, 2025, because Bunge borrowed to fund higher inventories. Bunge expects net interest expense of $640 to $670 million in 2026. The Viterra combination is large and complex. The combination raised the number of registered shares from about 134 million to about 193 million. If Bunge does not get the planned savings, earnings per share can stay low. Bunge has operations in Ukraine and other countries with war, sanctions or currency risk. In Q3 2026, it recorded charges and a tax valuation allowance because of the war in Ukraine. Results of Tropical Oils and Specialty Ingredients were lower in 2026 because of trade disruption and start-up costs, and Bunge lowered its 2026 outlook for this segment in October 2026.
- Balance sheet
- added: Cash: $524M Debt: $16.7B Net debt: $16.2B Undrawn credit line: $8.5B Debt due within 12 months: $7.8B Ratings: S&P A- (stable outlook), Moody's Baa1 (stable outlook), Fitch BBB+ (stable outlook) At September 30, 2026, Bunge had cash and cash equivalents of $524 million. Total debt was $16,746 million: short-term debt of $6,471 million and long-term debt of $10,275 million, of which $1,331 million is due within a year. Debt rose from $14,051 million at December 31, 2025, mainly to fund inventories after the South American harvest. Readily marketable inventories, which Bunge can sell for cash quickly, were $14,696 million. Bunge had $8,515 million of unused committed credit facilities. Its long-term debt ratings were A- from S&P, Baa1 from Moody's and BBB+ from Fitch, all with a stable outlook. In 2026, Bunge issued $1,800 million of senior notes due from 2031 to 2036. As of Sep 30, 2026.
- Checkpoints
- added: Jan 29, 2027 (estimate): Full-year 2026 results and 2027 outlook. Pending. Watch: 2026 adjusted EPS is within $9.25 to $9.75 and the first 2027 outlook is above the 2025 level of $7.57, and this passes; a 2027 outlook at or below $7.57 fails. 2027 (estimate): Viterra savings and Destrehan in the results. Pending. Watch: Bunge reports savings from the Viterra combination and profit from the new Destrehan processing line through 2027, and this passes; no clear savings fail.
- Recent events
- added: Oct 29, 2026: Bunge reported Q3 2026 adjusted EPS of $2.56, up from $2.27, and kept its 2026 outlook for adjusted EPS of $9.25 to $9.75. It said that the new oilseed processing line of Bunge Chevron Ag Renewables in Destrehan, Louisiana, started production after the quarter. Sep 17, 2026: Bunge extended three revolving credit facilities: $1.1 billion to October 2027, $4.2 billion to October 2031 and $3.5 billion to October 2029. Aug 31, 2026: Bunge agreed to sell its two sugarcane mills in Brazil to COFCO International for about $383 million. It recorded an impairment loss of $66 million. Aug 19, 2026: Bunge issued $600 million of 5.000% senior notes due 2031. Jul 29, 2026: Bunge reported Q2 2026 results and raised its 2026 outlook for adjusted EPS to $9.25 to $9.75, from $9.00 to $9.50. May 20, 2026: Shareholders approved a dividend of $2.88 per share, paid in four quarterly payments of $0.72, up 3% from $0.70. Apr 29, 2026: Bunge reported Q1 2026 adjusted EPS of $1.83 and raised its 2026 outlook for adjusted EPS to $9.00 to $9.50, from $7.50 to $8.00. Mar 9, 2026: The board approved a new share repurchase program of up to $3.0 billion, with no end date. Bunge bought back no shares in Q3 2026. Feb 4, 2026: Bunge reported 2025 adjusted EPS of $7.57, down from $9.19 in 2024, and gave a first 2026 outlook for adjusted EPS of $7.50 to $8.00.